

Scholarly Activities
American College of Physicians - Connecticut Chapter 2009
Achievements
- Best Oral Presentation: Harm Feringa
- Runner Up- Clinical Vignette: Shilpa Shetty
Ewa Kontny, M.D.; Victoria Costales, M.D.; Armin Sharokni, M.D.
Introduction:
Essential mixed cryoglobulinemia is a disorder of circulating immunoglobulins and complement complexes that precipitate in cold temperatures. This can be associated with many disorders including multiple myeloma, lymphoproliferative disorders, connective tissue diseases, infection, and liver disease. Since the discovery of hepatitis C virus it was established that nearly 5% of patients with chronic hepatitis C develop the syndrome. Aberrant immune response to chronic Hepatitis C infection seems to be the culprit behind widespread vasculitic changes.
Case presentation:
54 year old male with past medical history of hepatitis C (and failed interferon treatment), alcohol abuse, pancreatitis, bipolar disorder and intravenous drug abuse presented with 4 weeks of progressive lower extremity swelling difficult to control with diuretics and bullous rash. Renal biopsy showed changes consistent with membranoproliferative glomerulonephritis. Despite aggressive treatment with hemodialysis, plasmapheresis and eventually rituximab, the patient became more confused, developed respiratory distress and died. Initially 2 sets of cryoglobulins were negative with the last set confirming the diagnosis.
Conclusion:
Cryoglobulinemia associated with hepatitis C has a guarded prognosis. Acute mortality from essential mixed cryoglobulinemia is rare. If glomerulonephritis occurs in the course of disease, it is one of the worst prognostic signs with nearly 40% of patients suffering from fatal cardiovascular event, infection, or liver failure. Since many cases are associated with hepatitis C infection, it was noticed that clinical recovery is often dependent on antiviral treatment response (interferon alfa with ribavirin). Steroids offer complete remission in only about 7 % of cases. Plasmapheresis and cytotoxic agents have been used in anecdotal reports with variable response.
Ewa Kontny, M.D.; Dorothea Wild, M.D.
Flow cytometric techniques are routinely utilized in clinical hematology. When cells pass through a laser beam the light that emerges from each cell as it flows through is captured and analyzed to report cellular characteristics. It can be especially helpful in cases like our patient with normal cell morphology on peripheral blood smear where diagnosis could be nailed only by immunophenotyping-technique offered by flow cytometry.
Case Presentation:
The patient was a 87 years old white female with past medical history significant for hypertension, pulmonary hypertension and remote history of colon cancer. The patient had recently started seeing a hematologist for elevated platelets. For approximately 2 months she was taking 500 mg hydroxyurea daily until 3 days prior to admission when she was found to be mildly pancytopenic with a very low vitamin B12 level. Before her next follow up appointment patient presented to the hospital with complaints of fevers, chills and swelling with redness of the right sternoclavicular joint. CBC on admission revealed Hgb 8.3, Hct 23.9, WBC 1.8 with 46% granulocytes, 2% bands, 14% monocytes, 2% meta, 1% myelo, PLT 186, MCV 112.7, rouleaux noted. LDH 3170 (UNL-610), alk phosph 138 (UNL-127). Admission x-ray of the affected clavicle showed only degenerative changes. MRI showed edema surrounding the right sternoclavicular joint with bone marrow edema noted. CT-guided aspiration of the joint fluid did not show any gross pathologic findings. Patient’s swelling started to go down and she seemed to be doing well until 10-th day of the hospital stay when patient developed acute respiratory failure necessitating intubation and transfer to ICU. Repeat CT of the chest revealed new bilateral patchy airspace opacities imposed on interstitial lung disease and new left lower lobe infiltrate. Flow cytometry report came back with results showing approximately 20-25 % of circulating cells to be myeloblasts expressing CD34, dimCD33, CD117, CD13, MPO and HLADR, no lymphoid or monocytic markers. Given the history of myeloproliferative disease this could be evolution to acute myelogenous leukemia, FAB M1. Patient failed to wean from a ventilator, and her further hospital stay was complicated by essentially multiorgan failure. The patient eventually expired after comfort care extubation. Post mortem lung and bone marrow biopsy were consistent with acute leukemic process and leukemic infiltrate of the lungs.
Discussion:
The diagnosis of acute myelogenous leukemia (AML) is usually made by identification of leukemic blast cells. In our case, the morphology of the circulating white cells on the peripheral smear was normal, while flow revealed cells consistent with AML. Of note is that this patient likely suffered leukemic infiltrates of and signs and symptoms disrupted hematopoiesis. Pulmonary presentation is not very common-most often happens in FAB M5 leukemia-but as outlined in case report by Dr. Vlad pneumonia-like picture with subsequent respiratory failure can be a presenting complaint of some subset of patients with hematologic malignancies. 5 A high index of suspicion is necessary when approaching any older patient with non specific complaints and previous hematologic malignancy history treated with chemotherapy-even if typical features of acute malignancy are absent on peripheral blood smear.
Fifteen months prior to presentation, the patient was admitted for bright red blood per rectum. Endoscopy showed Barrett’s esophagus and colonoscopy showed now bleed sources. In the subsequent months, the patient continued to have decreasing hemoglobin and hematocrit. Three months prior to presentation, the patient became thrombocytopenic with a macrocytic anemia. Work up of the anemia showed negative anti-cardiolipin antibodies, within normal limits C3, C4, SPEP, UPEP, and negative cryoglobulins. Immunoelectrophoresis showed no monoclonal component. Peripheral smear showed… Flow cytometry was normal. Bone marrow biopsy showed all cell lines with decreased megakaryocytes but otherwise no abnormalities. The patient was treated with a 2-week course of Prednisone 60 mg, with no effect. Three more subsequent BMBs were done which were all normal.
Discussion:
The three major etiologies of anemia are decreased production of RBCs (bone marrow failure), increased destruction (intravascular/extravascular hemolysis), and blood loss. The patient’s four normal bone marrow biopsies rules out bone marrow failure. Multiple endoscopies showed no bleeding source. The differential diagnosis of hemolytic anemia is relevant to the patient’s diagnosis. Hemolytic anemias can be inherited or acquired. Hemolysis predominantly occurs either intravascularly or extravascularly. Inherited intravascular hemolytic anemias include hemoglobinopathies (hereditary spherocytosis) and enzymopathies (G6PD deficiency) while inherited extravascular disease familial hemolytic uremic syndrome. Acquired intravascular hemolysis is seen in paroxysmal nocturnal hemoglobinuria while acquired extravascular factors are involved in hemolytic anemias secondary to mechanical destruction, toxic agents, drugs, infectious causes and autoimmune.Hereditary hemolytic anemias are ruled out in the patient because the peripheral smear did not reveal spherocytes and elliptocytes. Among the acquired hemolytic anemias, mechanical destruction is ruled out because the patient does not have prosthetic heart valve. The patient does not take hemolysis-inducing medications. Infectious causes such as malaria and Shiga-toxin producing Escherichia coli are also ruled out. Autoimmune hemolytic anemia is also ruled out because of the patient’s negative cardiolipin antibodies (seen in systemic lupus erythematosus) and coombs negative test.
Griffin hospital, Derby, Connecticut
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an uncommon acquired disorder of peripheral nerves causing relapsing and remitting or progressive weakness and loss of sensation of limbs. Many clinical trials have been conducted in an effort to find a potential cure for this autoimmune debilitating illness.
A 72 year old male presented with progressive weakness of both legs two weeks after receiving vaccine for tetanus and pneumonia. The patient first noticed a cold sensation in the hands along with numbness and “wet sensation” in the legs. He was initially diagnosed with Guillaine Barre syndrome after spinal tap and nerve conduction studies. However, weakness in all the four limbs continued to progress over the next three months.
This case illustrates the role of IVIG in remission and initial improvement in CIDP.
IVIG (Gamunex) has been approved by the US FDA as a first line treatment for CIDP to improve neuromuscular impairment and for maintenance therapy to prevent relapse after the success of Immune Globulin Intravenous efficacy (ICE) trial.
Matxalen Amezaga, Armin Shahrokni, Seema D’souza.
CASE: The patient is a 45 year old male with a history of uncontrolled diabetes mellitus type 2, HTN and tobacco abuse for 30 years who presented to the ER with sudden onset of pleuritic left sided chest pain not associated with physical exertion, daily morning productive clear/white cough for the past year, which he attributed to smoking and 20 pounds weight loss for the past 6 months. He denied any SOB, palpitations, syncope, diaphoresis, hemoptisis, fever or chills. He was adopted and his family history is unknown. He denied alcohol or drug abuse. He used to work for the US army in Kentucky and Alabama and was exposed to a person with tuberculosis 5 years ago. His is married and had multiple extramarital sexual contacts. His has 2 cats and has no history of recent travels. His vitals signs and physical exam on admission were normal. His WBC was 11,400 cells/mm2 with 55% granulocytes, 31.3% lymphocytes, Eosinophyles 5.4%; H/H 11.1/34.1, MCV 65.4 and RDW 16.7. His BMP and LFT’s were normal. Cardiac work-up for ACS was negative. ANA was negative, ERS was 4. His HBA1C was 10.2. HIV test was negative. CXR showed focal opacity in left midlung with relative lucency and questionable cavitation. CT scan of the chest without IV contrast showed multiple cavitary lesions in the left lung in upper and lower lobes with air-fluid levels and thickened walls with innumerable lung nodules within the adjancent left upper and lower lobes with tree bud configuration, small left pleural effusion, very small few right lung nodules and single subpleural cyst right lung apex. AFB smears and sputum cultures came back positive for mycobacterium tuberculosis and the patient was started on Isoniazide, Rifampin, Ethambutol and Pyrazinamide.
DISCUSSION: The global incidence of TB appears to be declining since 2003. Poverty, HIV and drug resistance are major contributors factors to the prevalence of TB in the world. Poorly controlled diabetes as well as heavy smoking increases the relative risk of reactivation of tuberculosis. In 2008 among persons with TB with an HIV test result, 10.7% were infected with HIV. MDR TB represents 1% of the TB population affecting disproportionately foreign-born persons. The recommended length of drug therapy is 6-9months. In 2005 83% of patients for whom less or 1 yea of treatment was indicated completed therapy within 1 year, which is bellow the target set by the Health People 2010. There are different risks factors for TB and the disproportion of TB rates in the populations in the US, might be explained by the low knowledge concerning Tb transmission and curability in the high risk population that may translate into low levels of care seeking among those with TB symptoms and results in increased transmission or deaths due to late diagnoses. Different strategies must been included in the control of TB starting from physician and patient education, infection control measures, screening of high risk population and use of DOT.
Harm Feringa, Usha Emani, Miraude Adriaensen, Afrooz Ardestani, Shilpa Shetty, William Pearson
Aim: This study sought to evaluate the effect of CCB treatment for the primary prevention of PAD in patients with hypertension.
Methods: We searched the published literature (MEDLINE, the Cochrane Central Register of Controlled Trials and EMBASE) for trials published after 1990 reporting the effect of CCB on the development of PAD. Criteria for inclusion included a study duration of more than 6 months, the use of a randomized control group not receiving CCB, and the availability of outcome data on PAD. We conducted a meta-analysis with random and fixed effect models to combine and summarize the results of these studies.
Results: Of 2,006 potentially relevant studies, a total of 7 studies (65,925 patients) met our inclusion criteria. Patients randomized to the control group received either placebo or active treatment with ACE-inhibitors, beta-blockers or diuretics. In patients receiving CCB, 535 out of 24,678 (2.2%) developed PAD versus 1,249 out of 39,833 (3.1%) in the control group. CCB treatment was associated with a risk reduction of 25% for the development of PAD (95% confidence interval CI 33% to 17%, p<0.001). In the subset of 6 studies with 64,511 participants taking dihydropyridines vs control, dihydropyridines were associated with a risk reduction of 26% for the development of PAD (95% CI 33% to 18%, p<0.001).
Conclusion: Based on the results of this study, calcium-channel blockers appear to be effective in the prevention of PAD in patients with hypertension.
Case Presentation: An 82 year old female with a history of hypoglycemia which was thought to be secondary to an insulinoma presented to the ER complaining of weakness and a low blood sugar of 45 inspite of frequent snacking and proglycem. She also complained of a couple of episodes of nausea, vomiting and diarrhea. She had a past medical history significant for hypertension, dyslipidemia, lumbar disc prolapse, left adrenal nodule (ruled out for pheochromocytoma), GERD, TIA and presumed non localized insulinoma (due to high insulin levels and hypoglycaemic episodes). There was a family history of diabetes and thyroid cancer in her sister. Her medications included aggrenox, atenolol, spironolactone and proglycem. On physical examination her BP was 120/80, pulse 79, temperature 97.2F. The rest of the physical examination was essentially normal. Her proglycem was continued and she was started on a 5% dextrose drip. Evaluation of hypoglycaemia included an MRI of the abdomen which was negative for any mass lesions. C peptide levels were elevated (6.7 ng/ml) and insulin levels were also elevated (18 uIU/ml). Anti insulin antibodies were checked and were also found to be high (81%). On Serum electrophoresis the patient was noted to have monoclonal gammopathy characterised as IgG lambda (0.37 G/DL). She was treated with steroids to which she responded well with resolution of her recurrent hypoglycemic episodes.
Conclusion: Insulin autoimmune syndrome is a rare cause of hypoglycemia in the western population. Although there is some evidence indicating a genetic predisposition and linking this disease to HLA – DR4 in Japanese patients, most cases are associated with use of sulfhydryl- containing medications with a few reported cases occurring after use of the dietary supplement alpha lipoic acid. We propose that that the insulin antibodies detected in our patient are secondary to plasma cell dyscrasia. One should consider plasma cell dyscrasia induced insulin antibodies as a cause of recurrent hypoglycemia, particularly in elderly patients in whom an insulinoma is less likely as it may spare the patient an unnecessary pancreatic surgical procedure.
Neetu Nebhwani M.D, Joseph K Lim , M.D.
Case Report: A 58 y/o old male with history of chronic Hepatitis C infection with treatment failure on Interferon and Ribavirin presented with 2 days of easy bruisability, gum bleeding and mouth sores on 5/13/07. He denied any fever, chills, night sweats, any recent viral illness, travel, sick contacts, and no blood in stools or urine. His past medical history includes Chronic hepatitis C infection , genotype 1 and stage 2 on liver biopsy who is non responder to standard IFN plus ribavirin , and is now non responder to PEG-IFN plus Ribavirin which was discontinued on 4/27/07. Socially patient was a heavy alcohol abuser in the past and IV drug abuser as well. At the time of admission, vitals were stable, and physical examination revealed wet purpura with mucosal hemorrhage on left lower gum and pharynx and central tongue, left gum and buccal mucosa were also involved. Patient also had scattered non blanching petehiae. Rest of the physical examination was within normal limits. Labs at the time of admission showed WBC of 4.1, Hematocrit of 42 % and platelet count was undetectable. Most recent platelet count was 135 on 3/19/07. Peripheral smear was not notable for platelets, and no schitocytes were visualized. Further work up for hemolysis and DIC were negative. Extensive evaluation for thrombocytopenia was undertaken including viral studies for HIV, Hepatitis B, EBV, and CMV which were negative. CT scan of chest, abdomen and pelvis was done which did not demonstrate any evidence of lymphoma. Platelet associated IgG antibody were negative. Bone marrow biopsy was deferred at this point and patient was empirically started on IV solumedrol and he was also given 2 doses of WinRho? (Rho (D) immune globulin). During the Hospital course patient’s platelet increased to 34 confirming the response to the treatment with solumedrol and WinRho? and our suspicion about the ITP.
Discussion:Severe thrombocytopenia is being described in patients who are treated with Interferon and Ribavirin for hepatitis C. In this patient we saw profound thrombocytopenia secondary to Idiopathic thrombocytopenic purpura which decreased platelet levels to undetectable requiring hospitalization. Although the underlying trigger for this event remains unclear, suspecting that an idiopathic immune –mediated event following PEG-IFN withdrawal may have been a contributing factor although this has not been established definitively, and this would be considered an exceedingly rare and reportable observation in literature.
Karthikeyan Kandavelou, Neetu Nebhwani and Marya K. Chaisson
Department of Medicine, Griffin Hospital, Derby, CT 06418
Hepato-cellular carcinoma (HCC) is one of the most common malignancies worldwide, presenting with high incidence in regions where there is high prevalence of viral hepatitis, especially hepatitis B. HCC is usually diagnosed based on the typical Computed Tomographic CT appearance of hypervascular liver lesion and elevated serum AFP. Typical presentation of patients with HCC is right upper quadrant pain, upper gastrointestinal bleeding, hepatomegaly, jaundice and weight loss. HCC generally tends to metastasize late in its course. Common sites of metastasis of HCC are lungs, lymph nodes, adrenal glands and bones including the skull. HCC has a very aggressive clinical course with a mean survival of <1 year if left untreated. Here we report an unusual case of occult HCC diagnosed after biopsy of a metastasized mass on the left pedicle of L1 vertebra.
Case Report:
HCC was an accidental finding in this 63 year old gentleman who presented to our Emergency Department with Pneumonia. The unresolved right lobar consolidation initiated the workup for lung mass which led to the identification of isolated lytic lesion on the L1 vertebra. Malignancy work up showed an increase in Alpha Feto Protein (AFP), which raised the question of carcinoma of testicular origin. Subsequent ultrasound of the testes showed no evidence of mass lesions. Initial CT scan did not show any significant hepatic lesions. No significant activity in the liver was noticed on the PET scan. Pathological studies of the CT guided bone biopsy from the lumbar vertebra were suggestive of HCC which prompted the need for a CT scan performed with hepatic mass protocol. This showed multipe small, indeterminate lesions without a significant mass to suggest the presence of hepatic malignancy.
Discussion:
The three different routes of the spread of HCC are: hematogenous, lymphatic embolization and direct extension to neighboring structures. Hematogenous spread to lungs is the most common route and direct infiltrating metastasis is the least common. A retrospective study of 482 patients with HCC, 65 of them (13.48%) had extrahepatic metastases to the lungs (53.8%), the bones (38.5%), and the lymph nodes (33.8%). Naturally, patients with extrahepatic metastasis have more advanced disease, with a median survival time of 7 months (range 1-59 months) and a survival rate of 24.9%. The case we report here presented an unusual course of HCC. But the failure of the initial work up to detect the primary malignancy required a more aggressive work up.
Palak Shah M.D , Neetu Nebhwani M.D
Case Report:
A 38 year old male presented with c/o chronic epigastric burning pain, which was relieved by food intake and antacids. Additionally, he exhibited anasarca and weight gain, which were successfully treated with Lasix. He was also prescribed anatacids and protein supplements for albumin level of 1.8 gm/dl. He had no nausea, vomiting, dysphagia, and denied any diarrhea, constipation, blood per rectum or melena. The patient had no significant past medical or surgical history. No family history of colon cancer, polyp, IBD or celiac disease. The patient smoked and drank alcohol occasionally. On physical examination the patient was found to be thin, although not malnourished, rest of examination was not significant. On laboratory data, he recorded total protein level of 5.6 gm/dl and albumin level of 3.2 gm/dl and mild iron deficiency anemia. RPR and H.pylori antibody were negative. CT scan of abdomen and pelvis which was done to rule out pelvis mass had revealed questionable thickening of small bowel, jejunum and sigmoid colon. EGD showed erythmatous gastric body and fundus with hypertrophic folds, whereas esophageal mucosa and gastric antrum were grossly normal. Biopsy specimen of gastric body and fundus revealed reactive gastropathy with foveolar hyperplasia, which was consistent with Ménétrier's Disease. Antipariental cells and anti-Intrinsic factor antibodies were negative, Gastrin level was checked and H.Pylori antibody was rechecked. Patient was given Octreotide Injections, antacids and protein supplements. Patient is doing well with medical treatment at this point, so surgical treatment is deferred.
Conclusion:
Menetrier’s disease, although rare, should be included as a differential for clinical presentation of epigastric pain, edema and hypoalbuminemia. The characteristic feature is hypertrophic gastric folds. Treatment for the patients with Ménétrier disease includes supportive treatment with antacid, protein supplements and H.pylori eradication. Also, Octreotide - a somatostatin analog and Cetuximab – which is an EGF- R blocker, can be effective treatment options in some patients. When condition does not respond to medical treatment, surgical treatment such as partial gastrectomy should be considered. This not only improves quality of life by giving symptomatic relief and preventing loss of protein, but it also reduces the risk of gastric carcinoma.
Shilpa Bhardwaj M.D, Neetu Nebhwani M.D



